PPIG and cancer: The results from the two phase 1 open-label crossover studies in healthy subjects reported here (study 1 and study 2) provided key insights regarding the likelihood of DDIs between rezafungin for injection, a novel echinocandin, and CYP substrates and/or transporter proteins, immunosuppressants, and cancer therapies.